• 1
    Kinzler KW,Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 15970.
  • 2
    Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 3
    Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans 2005; 33: 6725.
  • 4
    Morin PJ,Sparks AB,Korinek V,Barker N,Clevers H,Vogelstein B,Kinzler KW. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275: 178790.
  • 5
    van den Brink GR,Offerhaus GJ. The morphogenetic code and colon cancer development. Cancer Cell 2007; 11: 10917.
  • 6
    Johnson V,Volikos E,Halford SE,Eftekhar Sadat ET,Popat S,Talbot I,Truninger K,Martin J,Jass J,Houlston R,Atkin W,Tomlinson IP, et al. Exon 3 β-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 2005; 54: 2647.
  • 7
    Tan LP,Ng BK,Balraj P,Lim PK,Peh SC. No difference in the occurrence of mismatch repair defects and APC and CTNNB1 genes mutation in a multi-racial colorectal carcinoma patient cohort. Pathology 2007; 39: 22834.
  • 8
    Suraweera N,Robinson J,Volikos E,Guenther T,Talbot I,Tomlinson I,Silver A. Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer 2006; 119: 183742.
  • 9
    Thorstensen L,Lind GE,Lovig T,Diep CB,Meling GI,Rognum TO,Lothe RA. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 2005; 7: 99108.
  • 10
    Akagi K,Uchibori R,Yamaguchi K,Kurosawa K,Tanaka Y,Kozu T. Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun 2007; 352: 72832.
  • 11
    Noda H,Kato Y,Yoshikawa H,Arai M,Togashi K,Nagai H,Konishi F,Miki Y. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers. J Exp Clin Cancer Res 2006; 25: 23542.
  • 12
    Oliveira C,Westra JL,Arango D,Ollikainen M,Domingo E,Ferreira A,Velho S,Niessen R,Lagerstedt K,Alhopuro P,Laiho P,Veiga I, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 230311.
  • 13
    Fang JY,Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 3227.
  • 14
    Nagasaka T,Sasamoto H,Notohara K,Cullings HM,Takeda M,Kimura K,Kambara T,MacPhee DG,Young J,Leggett BA,Jass JR,Tanaka N, et al. Colorectal cancer with mutation in BRAF. KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 458494.
  • 15
    Davies H,Bignell GR,Cox C,Stephens P,Edkins S,Clegg S,Teague J,Woffendin H,Garnett MJ,Bottomley W,Davis N,Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 94954.
  • 16
    Carpenter CL,Cantley LC. Phosphoinositide kinases. Biochemistry 1990; 29: 1114756.
  • 17
    Philp AJ,Campbell IG,Leet C,Vincan E,Rockman SP,Whitehead RH,Thomas RJ,Phillips WA. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 74269.
  • 18
    Campbell IG,Russell SE,Choong DY,Montgomery KG,Ciavarella ML,Hooi CS,Cristiano BE,Pearson RB,Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 767881.
  • 19
    Nosho K,Yamamoto H,Takahashi T,Mikami M,Taniguchi H,Miyamoto N,Adachi Y,Arimura Y,Itoh F,Imai K,Shinomura Y. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 2007; 28: 136470.
  • 20
    Samuels Y,Wang Z,Bardelli A,Silliman N,Ptak J,Szabo S,Yan H,Gazdar A,Powell SM,Riggins GJ,Willson JK,Markowitz S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
  • 21
    Ollikainen M,Gylling A,Puputti M,Nupponen NN,Abdel-Rahman WM,Butzow R,Peltomaki P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 2007; 121: 91520.
  • 22
    Samuels Y,Diaz LA,Jr,Schmidt-Kittler O,Cummins JM,Delong L,Cheong I,Rago C,Huso DL,Lengauer C,Kinzler KW,Vogelstein B,Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 56173.
  • 23
    Wang J,Kuropatwinski K,Hauser J,Rossi MR,Zhou Y,Conway A,Kan JL,Gibson NW,Willson JK,Cowell JK,Brattain MG. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther 2007; 6: 114350.
  • 24
    Samowitz WS,Slattery ML,Sweeney C,Herrick J,Wolff RK,Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007; 5: 16570.
  • 25
    De Galitiis F,Cannita K,Tessitore A,Martella F,Di Rocco ZC,Russo A,Adamo V,Iacobelli S,Martinotti S,Marchetti P,Ficorella C,Ricevuto E. Novel P53 mutations detected by FAMA in colorectal cancers. Ann Oncol 2006; 17( Suppl 7): vii78vii83.
  • 26
    Halazonetis TD,Gorgoulis VG,Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 13525.
  • 27
    Besse B,Ropert S,Soria JC. Targeted therapies in lung cancer. Ann Oncol 2007; 18( Suppl 9): ix135ix142.
  • 28
    Saal LH,Johansson P,Holm K,Gruvberger-Saal SK,She QB,Maurer M,Koujak S,Ferrando AA,Malmstrom P,Memeo L,Isola J,Bendahl PO, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 75649.
  • 29
    Whitehead RH,Macrae FA,St John DJ,Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer Inst 1985; 74: 75965.
  • 30
    Whitehead RH,Jones JK,Gabriel A,Lukies RE. A new colon carcinoma cell line (LIM1863) that grows as organoids with spontaneous differentiation into crypt-like structures in vitro. Cancer Res 1987; 47: 26839.
  • 31
    Whitehead RH,Zhang HH,Hayward IP. Retention of tissue-specific phenotype in a panel of colon carcinoma cell lines: relationship to clinical correlates. Immunol Cell Biol 1992; 70(Part 4): 22736.
  • 32
    Sizeland AM,Burgess AW. The proliferative and morphologic responses of a colon carcinoma cell line (LIM 1215) require the production of two autocrine factors. Mol Cell Biol 1991; 11: 400514.
  • 33
    Vincan E,Darcy PK,Farrelly CA,Faux MC,Brabletz T,Ramsay RG. Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids. Oncogene 2007; 26: 234052.
  • 34
    Lachal S,Ford J,Shulkes A,Baldwin GS. PPARα agonists stimulate progastrin production in human colorectal carcinoma cells. Regul Pept 2004; 120: 24351.
  • 35
    Andrew SM,Teh JG,Johnstone RW,Russell SM,Whitehead RH,McKenzie IF,Pietersz GA. Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). Cancer Res 1990; 50: 522530.
  • 36
    Whitehead RH,van Eeden P,Lukeis RE. A cell line (LIM 2463) derived from a tubulovillous adenoma of the rectum. Int J Cancer 1991; 48: 6936.
  • 37
    Usadel H,Brabender J,Danenberg KD,Jeronimo C,Harden S,Engles J,Danenberg PV,Yang S,Sidransky D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62: 3715.
  • 38
    Krypuy M,Ahmed AA,Etemadmoghadam D,Hyland SJ,DeFazio A,Fox SB,Brenton JD,Bowtell DD,Dobrovic A. High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007; 7: 168.
  • 39
    Faragher IG,Whitehead RH. Rapid diagnostic test for hereditary nonpolyposis colon cancer kindred using polymerase chain reaction. Dis Colon Rectum 1998; 41: 93840.
  • 40
    Vecsey-Semjen B,Becker KF,Sinski A,Blennow E,Vietor I,Zatloukal K,Beug H,Wagner E,Huber LA. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene 2002; 21: 464662.
  • 41
    Yang AD,Fan F,Camp ER,van Buren G,Liu W,Somcio R,Gray MJ,Cheng H,Hoff PM,Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 414753.
  • 42
    Russo A,Bazan V,Iacopetta B,Kerr D,Soussi T,Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23: 751828.
  • 43
    Zhao L,Vogt PK. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008; 105: 26527.
  • 44
    Yokoyama N,Yin D,Malbon CC. Abundance, complexation, and trafficking of Wnt/β-catenin signaling elements in response to Wnt3a. J Mol Signal 2007; 2:11.
  • 45
    Bafico A,Liu G,Yaniv A,Gazit A,Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001; 3: 6836.
  • 46
    Mao B,Wu W,Davidson G,Marhold J,Li M,Mechler BM,Delius H,Hoppe D,Stannek P,Walter C,Glinka A,Niehrs C. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 2002; 417: 6647.
  • 47
    Favata MF,Horiuchi KY,Manos EJ,Daulerio AJ,Stradley DA,Feeser WS,Van Dyk DE,Pitts WJ,Earl RA,Hobbs F,Copeland RA,Magolda RL, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 1862332.
  • 48
    Vlahos CJ,Matter WF,Hui KY,Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 52418.
  • 49
    Sparks AB,Morin PJ,Vogelstein B,Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 11304.
  • 50
    Suzuki H,Watkins DN,Jair KW,Schuebel KE,Markowitz SD,Chen WD,Pretlow TP,Yang B,Akiyama Y,Van Engeland M,Toyota M,Tokino T, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 41722.
  • 51
    Rodriguez-Viciana P,Warne PH,Dhand R,Vanhaesebroeck B,Gout I,Fry MJ,Waterfield MD,Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 52732.
  • 52
    Haigis KM,Kendall KR,Wang Y,Cheung A,Haigis MC,Glickman JN,Niwa-Kawakita M,Sweet-Cordero A,Sebolt-Leopold J,Shannon KM,Settleman J,Giovannini M, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 6008.
  • 53
    Wang D,Boerner SA,Winkler JD,LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007; 1773: 124855.